Urology & uro-oncology

Ferring is committed to the development of medicines to treat urological disorders such as diabetes insipidus, enuresis and nocturia. Ferring’s lead product in this area is MINIRIN^® (desmopressin) which effectively treats central diabetes insipidus and primary nocturnal enuresis in children¹, while NOCDURNA^® (low dose desmopressin) is approved for nocturia in adults. A vasopressin receptor agonist designed to bring additional treatment benefits in this therapy area is in early stage development.²

For the treatment of patients with advanced prostate cancer, Ferring has launched a 1-month dosing regimen of FIRMAGON^® (degarelix), a gonadotropin-releasing hormone (GnRH) receptor antagonist ³ , in the US, Europe, and through a partner in Japan, as well as other Asia Pacific countries. We are conducting clinical studies to further demonstrate the benefits of therapy using a (GnRH) receptor antagonist in the treatment of advanced prostate cancer.

References